The Time to Progression in Lung Adenocarcinoma Patients Receiving First- and Second-Generation EGFR-TKI in Indonesia

The Time to Progression in Lung Adenocarcinoma Patients Receiving First- and Second-Generation EGFR-TKI in Indonesia

Introduction: Targeted therapy, particularly epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), is the first-line treatment for non-small cell lung cancer (NSCLC). However, drug resistance has grown in the last few decades. This study compared the progression time of lung cancer...

Full description

Saved in:
Bibliographic Details
Main Authors: Elisna Syahruddin, Noni Novisari Soeroso, Fannie Rizki Ananda, Laksmi Wulandari, Ana Rima Setijadi, Sabrina Ermayanti, Suryanti Dwi Pratiwi, Andreas Infianto, Novita Andayani, Sri Melati Munir, Avissena Dutha Pratama, Ida Ayu Jasminarti Dwi Kusumawardani, Haryati Haryati, Natalie Duyen, Muhammad Alfin Hanif, Darren Wan-Teck Lim
Format: Article
Language:English
Published: Universitas Airlangga 2025-01-01
Series:Jurnal Respirasi
Subjects:
cancer
egfr-tki
lung adenocarcinoma
progression-free survival
time to progression
Online Access:https://e-journal.unair.ac.id/JR/article/view/64531
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://e-journal.unair.ac.id/JR/article/view/64531

Similar Items